- Home
- BRLT vs VYNE Comparison
BRLT vs VYNE Comparison
Compare BRLT & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | VYNE |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 20.1M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRLT | VYNE |
|---|---|---|
| Price | $1.32 | $0.60 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $1.70 | N/A |
| AVG Volume (30 Days) | 45.8K | ★ 178.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.21 | $0.29 |
| 52 Week High | $3.10 | $1.98 |
Technical Indicators
Market Signals| Indicator | BRLT | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 54.81 |
| Support Level | $1.25 | $0.56 |
| Resistance Level | $1.66 | $0.75 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.82 | 65.91 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.